These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11253617)

  • 1. An identifiability analysis of a parent-metabolite pharmacokinetic model for ivabradine.
    Evans ND; Godfrey KR; Chapman MJ; Chappell MJ; Aarons L; Duffull SB
    J Pharmacokinet Pharmacodyn; 2001 Feb; 28(1):93-105. PubMed ID: 11253617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacokinetic simulation model for ivabradine in healthy volunteers.
    Duffull SB; Chabaud S; Nony P; Laveille C; Girard P; Aarons L
    Eur J Pharm Sci; 2000; 10(4):285-94. PubMed ID: 10838018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model-based approaches for ivabradine development in paediatric population, part II: PK and PK/PD assessment.
    Peigné S; Fouliard S; Decourcelle S; Chenel M
    J Pharmacokinet Pharmacodyn; 2016 Feb; 43(1):29-43. PubMed ID: 26578442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a sequential linked pharmacokinetic and pharmacodynamic simulation model for ivabradine in healthy volunteers.
    Duffull SB; Aarons L
    Eur J Pharm Sci; 2000; 10(4):275-84. PubMed ID: 10838017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Silibinin on the Pharmacokinetics of Ivabradine and N-Desmethylivabradine in Rats.
    Chen XP; Zheng HT; Cai WW; Li MK; Zhang JW; Hu J
    Pharmacology; 2015; 96(3-4):107-11. PubMed ID: 26202095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessment.
    Peigné S; Bouzom F; Brendel K; Gesson C; Fouliard S; Chenel M
    J Pharmacokinet Pharmacodyn; 2016 Feb; 43(1):13-27. PubMed ID: 26563503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers.
    Ragueneau I; Laveille C; Jochemsen R; Resplandy G; Funck-Brentano C; Jaillon P
    Clin Pharmacol Ther; 1998 Aug; 64(2):192-203. PubMed ID: 9728900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics-pharmacodynamics during drug development--an example from Servier: ivabradine.
    Laveille C; Jochemsen R
    Therapie; 2004; 59(2):173-7. PubMed ID: 15359608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of oral ivabradine in healthy cats.
    Riesen SC; Ni W; Carnes CA; Lindsey KJ; Phelps MA; Schober KE
    J Vet Pharmacol Ther; 2011 Oct; 34(5):469-75. PubMed ID: 21118419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population plasma and urine pharmacokinetics of ivabradine and its active metabolite S18982 in healthy Korean volunteers.
    Choi HY; Bae KS; Cho SH; Ghim JL; Choe S; Jung JA; Lim HS
    J Clin Pharmacol; 2016 Apr; 56(4):439-49. PubMed ID: 26265098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial.
    Portolés A; Terleira A; Calvo A; Martínez I; Resplandy G
    J Clin Pharmacol; 2006 Oct; 46(10):1188-94. PubMed ID: 16988208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous determination of ivabradine and its metabolites in human plasma by liquid chromatography--tandem mass spectrometry.
    François-Bouchard M; Simonin G; Bossant ; Boursier-Neyret C
    J Chromatogr B Biomed Sci Appl; 2000 Aug; 745(2):261-9. PubMed ID: 11043745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial.
    Portolés A; Calvo A; Terleira A; Laredo L; Resplandy G; Gorostiaga C; Moreno A
    J Clin Pharmacol; 2006 Oct; 46(10):1195-203. PubMed ID: 16988209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal design of a population pharmacodynamic experiment for ivabradine.
    Duffull SB; Mentré F; Aarons L
    Pharm Res; 2001 Jan; 18(1):83-9. PubMed ID: 11336357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
    Perry CM
    Am J Cardiovasc Drugs; 2012 Dec; 12(6):415-26. PubMed ID: 23181944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of demoxepam, a chlordiazepoxide metabolite, in the dog.
    Schwartz MA; Postma E; Kolis SJ
    J Pharm Sci; 1971 Mar; 60(3):438-44. PubMed ID: 5572124
    [No Abstract]   [Full Text] [Related]  

  • 17. Identifiable pharmacokinetic models: the role of extra inputs and measurements.
    Godfrey KR; Jones RP; Brown RF
    J Pharmacokinet Biopharm; 1980 Dec; 8(6):633-48. PubMed ID: 7229913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of clopidogrel on pharmacokinetics of ivabradine and its metabolite in rats.
    Sun W; Wang Z; Chen H; Zhang XD; Huang CK; Lian QQ; Shang-Guan WN; Zhu GH; Hu GX; Wang ZS
    Drug Dev Ind Pharm; 2015; 41(9):1512-7. PubMed ID: 25250618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of ivabradine and its N-demethylated metabolite in human plasma and urine, and in rat and dog plasma by a validated high-performance liquid chromatographic method with fluorescence detection.
    Klippert P; Jeanniot JP; Polvé S; Lefèvre C; Merdjan H
    J Chromatogr B Biomed Sci Appl; 1998 Nov; 719(1-2):125-33. PubMed ID: 9869372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers.
    Vlase L; Neag M; Popa A; Muntean D; Bâldea I; Leucuta SE
    J Clin Pharm Ther; 2011 Apr; 36(2):225-9. PubMed ID: 21366652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.